The portfolio maintains a sizable cost advantage over competitors, priced within the lowest fee quintile among peers.
Invesco Biotechnology & Genome ETF PBE
Morningstar’s Analysis PBE
Will PBE outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 44.5
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
United Therapeutics Corp | 5.28 | 14.0 Mil | Healthcare |
Illumina Inc | 5.21 | 13.8 Mil | Healthcare |
Alnylam Pharmaceuticals Inc | 5.05 | 13.4 Mil | Healthcare |
Amgen Inc | 5.03 | 13.4 Mil | Healthcare |
Biogen Inc | 4.91 | 13.0 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 4.46 | 11.8 Mil | Healthcare |
Biomarin Pharmaceutical Inc | 4.00 | 10.6 Mil | Healthcare |
Neurocrine Biosciences Inc | 3.92 | 10.4 Mil | Healthcare |
Xencor Inc | 3.36 | 8.9 Mil | Healthcare |
MannKind Corp | 3.28 | 8.7 Mil | Healthcare |